<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Sinonasal malignant melanoma is a rare, aggressive tumor, associated with a poor prognosis, accounting for 8-15% of all head and neck melanomas and 0.5-2% of all melanomas. The diagnosis is given by histopathological and immunological examination. Elective treatment consists of surgical excision with free resection borders, and adjuvant chemotherapy / radiotherapy / immunotherapy / checkpoint inhibitors can be used to control local recurrence and distant metastases. We chose to present the case of an unresectable ethmoidal malignant melanoma at the time of diagnosis, pembrolizumab treatment converting it to resectability, with improving patient’s quality of life, even if the patient developed an adrenal metastasis.</p>
</abstract>

Sinonasal malignant melanoma is a rare, aggressive tumor, associated with a poor prognosis, accounting for 8-15% of all head and neck melanomas and 0.5-2% of all melanomas. The diagnosis is given by histopathological and immunological examination. Elective treatment consists of surgical excision with free resection borders, and adjuvant chemotherapy / radiotherapy / immunotherapy / checkpoint inhibitors can be used to control local recurrence and distant metastases. We chose to present the case of an unresectable ethmoidal malignant melanoma at the time of diagnosis, pembrolizumab treatment converting it to resectability, with improving patient’s quality of life, even if the patient developed an adrenal metastasis.

Sinonasal malignant melanoma

“Iuliu Hatieganu” University of Medicine and Pharmacy

Romanian Journal of Rhinology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"Sinonasal malignant melanoma"}

Sinonasal malignant melanoma is a rare, aggressive tumor, associated with a poor prognosis, accounting for 8-15% of all head and neck melanomas and 0.5-2% of...

Sinonasal malignant melanoma

Publicado en línea: 18 jul 2022

Páginas: 135 - 139

Recibido: 10 abr 2022

Aceptado: 19 may 2022

DOI: https://doi.org/10.2478/rjr-2022-0020

Palabras clave
melanoma, sinonasal, ethmoid, unresectable, pembrolizumab

© 2022 Daiana Birta et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Sinonasal malignant melanoma

Publicado en línea: 18 jul 2022

Páginas: 135 - 139

Recibido: 10 abr 2022

Aceptado: 19 may 2022

DOI: https://doi.org/10.2478/rjr-2022-0020

Palabras clavemelanoma, sinonasal, ethmoid, unresectable, pembrolizumab

© 2022 Daiana Birta et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Palabras clave
melanoma, sinonasal, ethmoid, unresectable, pembrolizumab